Cochrane · systematic review · CD006352
Fluphenazine (oral) versus placebo for schizophrenia
Matar, HE, Almerie, MQ, Sampson, SJ · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsORAL FLUPHENAZINE versus PLACEBO for Schizophrenia
Population: patients with Schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Not improved or worsened ‐ medium termDichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) ORAL FLUPHENAZINE vs PLACEBO | RR 1.12 [0.79, 1.58] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Global state: Relapse ‐ long termClinical judgement ORAL FLUPHENAZINE vs PLACEBO | RR 0.39 [0.05, 3.31] | 2 studies · 86 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects: Death ‐ long termOccurrences of death ORAL FLUPHENAZINE vs PLACEBO | RR 2.38 [0.1, 55.72] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: Extrapyramidal effects (akathisia) ‐ short termInstances of akathisia ORAL FLUPHENAZINE vs PLACEBO | RR 3.43 [1.23, 9.56] | 2 studies · 227 participants | Moderate Downgraded: risk of bias |
Adverse effects: Extrapyramidal effects (rigidity) ‐ short termInstances of rigidity ORAL FLUPHENAZINE vs PLACEBO | RR 3.54 [1.76, 7.14] | 2 studies · 227 participants | Moderate Downgraded: risk of bias |